United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surface area. no adverse developmental effects were observed in offspring of rats administered repaglinide during late gestation and lactatio

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surface area. no adverse developmental effects were observed in offspring of rats administered repaglinide during late gestation and lactatio

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surface area. no adverse developmental effects were observed in offspring of rats administered repaglinide during late gestation and lactatio

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7.1)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7.1)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7.1)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: • concomitant use of gemfibrozil [see drug interactions (7.1)] • known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations ). teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - repaglinide - tablet - repaglinide 0.5 mg - drugs used in diabetes

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - repaglinide - tablet - repaglinide 2 mg - drugs used in diabetes

Israel - English - Ministry of Health

teva israel ltd - repaglinide - tablets - repaglinide 2 mg - repaglinide - treatment of type ii diabetes.